STAT+: Wegovy’s successful heart trial raises a vital question about weight loss
A landmark study that found the blockbuster obesity drug Wegovy reduces the chance of heart…
Category: STAT+
STAT+: ‘No data more personal’: Patients, digital health players weigh in on the FTC’s data privacy plan
This year has seen the Federal Trade Commission crack down on digital health companies’ irresponsible…
STAT+: More drugmakers are filing continuation patents that sideline generic competition
Amid concerns that the pharmaceutical industry unfairly wins monopolies on medicines, a new analysis finds…
STAT+: Pharmalittle: Novo’s Wegovy obesity drug lowers cardiovascular risk in key trial; Nektar accuses Lilly of ‘misconduct’ in development deal
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Beleaguered drug manufacturer Emergent cuts jobs, executive role in business shake-up
Emergent Biosciences, the manufacturing company that fell into hot water in 2021 due to a…
STAT+: Novo’s obesity drug Wegovy lowers cardiovascular risk by 20%, landmark trial finds
Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in…
.jpg)
STAT+: More regulation could be coming for drug ads
WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in…
STAT+: Nektar Therapeutics sues Lilly for ‘misconduct’ in drug development deal
A behind-the-scenes feud over a drug development program erupted into public view as Nektar Therapeutics…
STAT+: Sage considers ways to reduce costs following FDA rejection on drug for major depression
Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs,…
STAT+: Pharmalittle: FDA OKs Sage drug for postpartum depression; major U.S. health systems to offer Alzheimer’s drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA approves Sage Therapeutics’ rapid-acting medication for postpartum depression but not major depression
The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage…
STAT+: Pharmalittle: White House drug-shortage task force brainstorms fixes; U.S. pharma layoffs are ballooning
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Medicare slashes safety net hospital payments on estimate that more people have insurance
The federal government will pay hospitals that treat poor and uninsured patients almost $1 billion…
STAT+: For brain-computer interfaces, the commercial hurdles may be bigger than scientific ones
Rodney Gorham loves fast, flashy cars: His WhatsApp profile picture is a bright yellow Corvette…
STAT+: Alnylam reports growth in sales of rare disease treatments
Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in…
.jpg)
STAT+: Study proposing microbiome-based cancer diagnostic comes under fire
Micronoma, a San Diego-based biotech startup, was founded on the idea that signatures from microbes…
STAT+: Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries
Several Latino advocacy groups and more than 100 clinicians from dozens of countries are lending…
STAT+: White House drug shortage task force held rare in-person meeting with industry
WASHINGTON — A new White House task force on drug shortages held a rare in-person…
STAT+: Pharmalittle: Patients brace for insurance decisions on weight loss drugs; Indian authorities find multiple problems at pharma plants
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Startup Celsius cuts 75% of staff ahead of first trial start for IBD drug
Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate,…
STAT+: Pharma industry showers House GOP doctor with campaign cash
WASHINGTON — The pharmaceutical industry has been flooding the campaign coffers of Rep. Larry Bucshon, a…
STAT+: Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs….
STAT+: Vertex non-opioid therapy reduced pain in mid-stage trials, study shows
Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently,…
STAT+: With new acquisitions, Humana and CVS hope to turn members into patients
Both Humana and CVS Health on Wednesday touted plans to aggressively scale their primary care…
STAT+: Pharmalittle: Some employers cut insurance coverage for weight loss drugs; U.S. urges ADHD pill makers to boost production
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Intas Pharma employee used acid to destroy manufacturing records at troubled plant
Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are…
STAT+: Labor Department says UnitedHealth Group unit illegally denied emergency room, drug screen claims
The U.S. Department of Labor claims in a new lawsuit that a UnitedHealth Group unit…
STAT+: Private equity-owned physician groups plan lobbying push on mergers
Three large and growing physician groups backed by the private equity giant Welsh, Carson, Anderson…
STAT+: Verily hires former Apple Health leader Andrew Trister as chief scientific officer
As Verily aims to get on track, the Alphabet life science company has hired Andrew…
STAT+: Microsoft strikes partnership with Duke Health to advance AI in medicine
On Tuesday, Duke Health and Microsoft announced a five-year partnership that will support artificial intelligence…
STAT+: EQRx, failed developer of low-priced cancer drugs, is sold for cash
EQRx is done, sold for its cash. The once-buzzy but now dormant biotech company is being…
STAT+: Pharmalittle: Medicare looks to improve Alzheimer’s care but sidesteps drug prices; CVS to cut 5,000 jobs
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: How Y Combinator’s only health care partner decides which startups are worth a shot
This story is the first in a series of profiles of influential figures and decision-makers…
STAT+: Flow Neuroscience shows promising results in trial of brain-stimulation headset for depression
Flow Neuroscience, a small Swedish company treating depression with brain-stimulating headsets, released early data on…
STAT+: Medicare wants to improve Alzheimer’s care, but sidesteps drug prices
WASHINGTON — Medicare announced today a pilot program aimed at improving dementia care and reducing…
STAT+: Vivek Ramaswamy wants to ‘gut’ the FDA. His claims don’t hold up to scrutiny
STAT readers know Vivek Ramaswamy from his time as the founder of the biotech conglomerate…
STAT+: Pharmalittle: House Republicans and Democrats duel over drug shortages; FDA approves second over-the-counter naloxone
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: New safety details link Apellis eye drug to rare cases of blindness. Cause still unknown
Five elderly people have been blinded by a severe side effect after receiving injections of…
STAT+: Sage hopes for a blockbuster in fast-acting antidepressant now before FDA
Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her…
STAT+: Gene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution
WASHINGTON — Jennifer Puck has successfully treated 10 children with a gene therapy for a…
STAT+: House GOP offers new plan to stem drug shortages, including cancer drug shortages
WASHINGTON — House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats…
STAT+: Pharmalittle: Pharma hopes reformulated drugs will skirt Medicare negotiations; Biogen to acquire Reata for $7.3 billion
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Biogen to acquire Reata Pharmaceuticals in $7 billion deal
Biogen on Friday said it would acquire Reata Pharmaceuticals, the maker of an approved therapy…
STAT+: With profitability in sight, Talkspace is budding into a digital health success story
Virtual mental health company Talkspace on Thursday added to its run of promising earnings reports,…
STAT+: Midwest health systems Fairview and Sanford call off $14 billion merger
Sanford Health and Fairview Health Services have for the second time scrapped their planned merger,…
STAT+: Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly
More than two dozen prominent health policy experts are urging the Biden administration to ensure…
STAT+: Key Republicans nix idea to give FDA new power to regulate CBD
WASHINGTON – The Food and Drug Administration says it needs Congress to give it more…
STAT+: HCA says smaller share of spending going to labor
The chief executive of the country’s biggest hospital chain said Thursday that labor costs are…
STAT+: Scientists inch closer to single-shot gene editing cure for blood disorders
What is the best way to fix faulty blood cells, and do so for the…
STAT+: The once-hot market for biotech jobs and lab space has cooled. What now?
When Crystal Shih Byers left her job at Novartis in 2020, she was excited to…